| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
N-Bromoacetamide does not have a specific biological target as a drug; it is a chemical reagent. It has been reported to irreversibly deactivate sodium ion channels on the cytoplasmic surface of cell membranes and also reduce the rapid inactivation of potassium ion currents. However, these effects are related to its chemical reactivity as a brominating agent rather than specific receptor binding.
|
|---|---|
| ln Vitro |
In vitro, N-Bromoacetamide is not typically evaluated for biological activity as a drug; it is a chemical reagent. It has been reported to irreversibly deactivate sodium ion channels on the cytoplasmic surface of cell membranes and reduce the rapid inactivation of potassium ion currents. These effects are due to the compound's ability to brominate and modify channel proteins. However, it is not used as a pharmacological tool for these purposes.
|
| ln Vivo |
In vivo, N-Bromoacetamide is not evaluated for biological activity as a drug; it is a chemical reagent. It is not administered as a therapeutic agent. The compound is sensitive to light, moisture, and heat, and decomposes rapidly at elevated temperatures, making it unsuitable for in vivo applications.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for N-Bromoacetamide as a drug target. As a chemical reagent, it is characterized by its reactivity and ability to brominate organic compounds. The compound's brominating activity can be assessed by reaction with alkenes or other substrates, and the products are analyzed by NMR or mass spectrometry.
|
| Cell Assay |
There are no specific in vitro cellular assays for N-Bromoacetamide as a pharmacologically active compound. As a chemical reagent, it is not used in cell culture. The compound is reactive and can modify proteins and lipids, which would be cytotoxic. It is not suitable for cellular assays due to its reactivity and instability.
|
| Animal Protocol |
There are no specific in vivo animal studies for N-Bromoacetamide as a pharmacologically active compound. As a chemical reagent, it is not administered to animals. The compound is sensitive to light, moisture, and heat, and decomposes rapidly, making it unsuitable for in vivo applications.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N-Bromoacetamide are not applicable, as it is a chemical reagent rather than a drug. The compound is not intended for administration. Its chemical properties include a molecular weight of 137.96 and solubility in water and organic solvents.
|
| Toxicity/Toxicokinetics |
The toxicity profile of N-Bromoacetamide: The compound is classified as an irritant (Xi) with hazard statements R36/37/38 (irritating to eyes, respiratory system, and skin). It is sensitive to light, moisture, and heat, and decomposes rapidly at elevated temperatures, in the presence of moisture and light. The compound should be handled with care in a fume hood with appropriate personal protective equipment. It is not for human therapeutic use.
|
| References | |
| Additional Infomation |
N-Bromoacetamide is a white powder. (NTP, 1992)
N-Bromoacetamide (CAS 79-15-2, NBA) is a chemical reagent used in organic synthesis for bromohydration and bromofluorination of alkenes. It has a molecular formula of C2H4BrNO and a molecular weight of 137.96. The compound is a white crystalline solid, soluble in CHCl3, H2O, and THF, and is sensitive to light, moisture, and heat. It is classified as an irritant and should be handled with care. It is available for research use only. |
| Molecular Formula |
C2H4BRNO
|
|---|---|
| Molecular Weight |
137.9633
|
| Exact Mass |
136.948
|
| CAS # |
79-15-2
|
| PubChem CID |
4353
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.71 g/cm3
|
| Melting Point |
102-105°C
|
| Index of Refraction |
1.474
|
| LogP |
0.823
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
5
|
| Complexity |
44.9
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VBTQNRFWXBXZQR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C2H4BrNO/c1-2(5)4-3/h1H3,(H,4,5)
|
| Chemical Name |
N-bromoacetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~724.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2485 mL | 36.2424 mL | 72.4848 mL | |
| 5 mM | 1.4497 mL | 7.2485 mL | 14.4970 mL | |
| 10 mM | 0.7248 mL | 3.6242 mL | 7.2485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
